Lysophosphatidic acid (LPA) mediates pleomorphic effects on multiple cell lineages, including an increased proliferative response of ovarian cancer cells both in vitro and in vivo, at least in part through the novel expression of LPA receptors. Thus, LPA hydrolysis is necessary to limit the duration of LPA's action on multiple cell types, including ovarian cancer cells. We determined the principal mechanism of LPA hydrolysis by ovarian cancer cells and its regulation by GnRH, which is known to have antiproliferative actions on ovarian carcinomas. LPA-hydrolyzing activity in cell membranes of ovarian cancer specimens was assessed by measuring the conversion of ex-
homogenate fractions, respectively. The membrane phosphatase was Mg 2ϩ independent and insensitive to inhibition by N-ethylmaleimide, characteristics suggestive of phosphatidic acid phosphatase activity. Incubation of membranes from GnRH receptor-positive ovarian cancer specimens with the GnRH agonist, buserelin, induced a dosedependent increase in LPA phosphatase activity, with a half-maximal effect occurring with 30 nmol/L buserelin. The stimulatory action of buserelin could be neutralized by displacement of GnRH from its receptor by the GnRH antagonist, antide. The plasma membranes from GnRH receptor-negative ovarian cancer specimens did not respond to GnRH stimulation. LPA phosphatase activity was also increased when the ovarian cancer cell line Caov-3 was exposed to GnRH agonist in intact cells before assay of cell membranes. These data demonstrate that LPA is hydrolyzed in the plasma membrane of ovarian cancer cells by the action of LPA phosphatase and provide initial evidence for functional coupling of LPA phosphatase to GnRH receptor occupancy. L YSOPHOSPHATIDIC acid (LPA), the simplest phospholipid, mediates a wide range of functions, including enhanced cell growth, decreased cell death, increased cancer cell invasion, and improved wound healing and regeneration (1) (2) (3) . Previous reports have shown that ascetic fluid and plasma from patients with ovarian cancer contain high levels of LPA (4 -6) . LPA stimulates the proliferation of ovarian cancer cells; increases intracellular calcium release and tyrosine phosphorylation; activates multiple kinases, including mitogen-activated protein kinase and focal adhesion kinase; and increases the production of proteases involved in invasion and increases production of LPA itself (7, 8) . LPA also decreases chemotherapy-induced ovarian cancer cell death (9) . The effects of LPA on ovarian cancer cells may be mediated in part by the novel expression of LPA receptors by ovarian cancer cells (10) . Thus, LPA contributes to the pathophysiology and likely outcome of ovarian cancer. The contribution of LPA to multiple functions in ovarian cancer cells suggests that LPA levels may be tightly regulated in vivo. There are two possible LPA-hydrolyzing pathways, one via deacylation by (lyso)phospholipase and the other via dephosphorylation by (lyso)phosphatase (11) . Alternatively, LPA can also be converted to PA, which is also bioactive, through the action of endopilin (12) . It is, however, unclear which pathways contribute to LPA metabolism in vivo.
GnRH agonists inhibit the proliferation of ovarian cancer cells both in vivo and in vitro (13, 14) . GnRH-responsive ovarian carcinomas express functional GnRH receptors; however, the molecular mechanisms linking GnRH receptor occupancy to the growth-inhibiting activity remain unclear (15, 16) . We have shown that GnRH agonists decrease the phosphorylation of a membrane protein substrate through activation of a phosphoprotein phosphatase that is known to counteract protein phosphorylation and to promote cell growth (17, 18) . The objectives of this investigation were to define the pathway(s) mediating LPA degradation and determine whether the growth inhibitory activity of GnRH agonists on ovarian cancer cells was associated with alterations in LPA metabolism in surgically removed ovarian carcinomas and cloned ovarian cancer cell lines.
Materials and Methods Materials
The GnRH agonists, buserelin and leuprolide, were gifts from Hoechst Japan (Tokyo, Japan) and Takeda Pharmaceutical (Osaka, Japan), respectively. The GnRH antagonist, antide, TRH, oleolyl LPA, N-ethylmaleimide (NEM), orthovanadate (Na 3 VO 4 ), sphingosine 1-phosphate, ceramide 1-phosphate, guanosine-5Ј-O-(2-thiodiphos-phate) (GDP-␤-S), and guanosine-5Ј-O-(3-thiotriphosphate) (GTP-␥-S) were purchased from Sigma (St. Louis, MO). Mono-oleoyl- [9,10- 
Tissue collection and cell cultures
Ovarian carcinoma specimens were placed in ice-cold phosphatebuffered saline immediately after surgical removal, and representative portions were excised for histological frozen sections. These tissue samples were washed and immediately used or stored in liquid nitrogen. Only tissues obtained at initial surgery were used for analyses. We screened the surgical samples for the presence of GnRHbinding sites and GnRH receptor messenger ribonucleic acid as described previously (16) . Of a total of 12 samples (5 mucinous cystadenocarcinomas, 5 serous cystadenocarcinomas, and 2 clear cell carcinomas), 10 (5 mucinous cystadenocarcinomas, 4 serous cystadenocarcinomas, and 1 clear cell carcinoma) had obvious GnRH receptor expression. Clinical data and the results of GnRH receptor analyses are summarized in Table 1 . The investigation had the approval of the Gifu University research ethics committee, and all patients gave informed consent to the disposition of their surgically removed tissues. Aside from the diagnosis of ovarian carcinoma, these patients were free of endocrine or systemic diseases.
The human ovarian carcinoma cell line, Caov-3, was obtained from American Type Culture Collection (Manassas, VA); this cell line is GnRH receptor positive (16, 19) . The cells were grown at 37 C in an appropriate medium containing FBS in a humidified atmosphere of 5% CO 2 -95% air. To examine hormonal effects, the cells were grown to confluence in multiwell plates and treated with the indicated concentrations of test agents for the desired time intervals.
Plasma membrane isolation
The specimens (tumors surgically removed and cell pellet) were homogenized in 10 vol ice-cold lysis buffer (0.5 mmol/L dithiothreitol, 1 mmol/L ethyleneglycol tetraacetic acid, 1 mmol/L NaHCO 3 , and 10 mmol/L HEPES, pH 7.9) by brief sonication. Highly purified plasma membrane fractions from the homogenates were obtained as described previously (17, 18) . The isolated plasma membranes finally were resuspended in the lysis buffer and immediately submitted to the following experiments. Marker enzyme analyses were performed using 5Ј-nucleotidase as a marker for the plasma membrane and succinate dehydrogenase for mitochondria (20, 21) . Protein was determined according to Lowry's method (22) , using BSA as a standard. The specific activity of 5Ј-nucleotidase in the plasma membrane fraction was increased approximately 6-to 9-fold, compared to that of the homogenate (1-3 mol/mg protein⅐h); the specific activity of succinate dehydrogenase was decreased to approximately 1/10th that of the homogenate (650 pmol/mg protein⅐min).
Where indicated, the plasma membranes isolated from different ovarian carcinomas were pooled; pool 1 contained samples from cases 1-3, pool 2 from cases 4 -6, and pool 3 from cases 7-9 and 10. Pool 4 contained plasma membranes of tumors from cases 10 and 12 for GnRH receptornegative specimens. , and the indicated amount of enzyme (10 -100 g protein) as a final concentration (23) . In some experiments, the concentration of LPA was altered by the addition of nonradiolabeled oleoyl LPA. LPA was added after dispersal by brief sonication. The incubation was started by adding enzyme protein and was incubated at 37 C for the desired time intervals in the presence of the ligands to be tested. For the experiments with sphingosine 1-phosphate or ceremide 1-phosphate, these lipids were added after dispersal by brief sonication. The reaction was terminated by adding 4 vol chloroform-methanol (1:2, vol/vol), followed by 1 vol chloroform and 1 vol water. After the two phases were separated, the lower phases were dried under N 2 and applied to silica gel 60 plates. Plates were developed in chloroform-acetone (96:4, vol/vol) (20, 21) . Dried plates were exposed to iodine vapor to localize free fatty acid and monoglyceride fractions by comparison with authentic standards. The areas corresponding to individual lipids were scraped, and the radioactivity was determined. Under these conditions, less than 2% of the added substrate LPA was consumed. All experiments were performed in triplicate determinations.
LPA hydrolysis assay

Statistics
Statistical analysis was performed using one-way ANOVA in combination with Scheffe's test.
Results
LPA hydrolysis by phosphatase activity within plasma membrane
When the plasma membrane fraction isolated from ovarian carcinoma surgical specimens was incubated with exogenous [ 3 H-oleoyl]LPA, there was a time-dependent increase in mono-[ 3 H-oleoyl]glycerol (Fig. 1, upper panel) . Monoglyceride production persisted for at least 60 min. The apparent activity per mg protein in the plasma membrane was approximately 2.5-and 8-fold higher than those found in the microsome (crude membrane) and homogenate fractions, respectively. Table 1 summarizes the clinical data and LPA phosphatase activity of the ovarian carcinomas tested. All surgically removed specimens had significant LPA phosphatase activity.
Exposure of exogenous oleoyl LPA to plasma membranes resulted in a time-dependent increase in oleic acid levels. However, phospholipase activity was approximately 100-fold less than LPA phosphatase activity (Fig. 1, lower panel) . Hence, the predominant pathway of LPA metabolism by ovarian cancer cell membranes was dephosphorylation by LPA phosphates. (Fig. 2) . Analysis of the results with a double reciprocal plot yielded a maximum velocity of 6.41 nmol/mg protein⅐h and a K m for LPA phosphatase of 43.7 mol/L.
We then compared the sensitivity of the LPA phosphatase activity in ovarian cancer cell membranes to that reported for phosphatidic acid (PA) phosphohydrolase (PAP) (23) or lipid phosphatase activity in subcellular fractions (23) (24) (25) . Ca 2ϩ and Mn 2ϩ inhibited LPA dephosphorylation; both exhibited a 90% inhibitory effect at 2 mmol/L. Mg 2ϩ had no effect on enzyme activity up to 2 mmol/L, suggesting that the LPA phosphatase is Mg 2ϩ independent (Fig. 3) . Orthovanadate, a phosphatase transition state analog, inhibited LPA phosphatase activity by 90% when added at 10 mmol/L (Fig. 3) . NEM, known to inhibit purified PAP1 (23) (24) (25) , had no effect on phosphatase activity up to 5 mmol/L (Fig. 3) .
To explore substrate specificity, the effects of other lipid substrates were examined (Fig. 3) . Sphingosine 1-phosphate and ceramide 1-phosphate had no effect on LPA hydrolysis at a 4-fold higher concentration (200 mol/L) of the LPA substrate.
GnRH agonist stimulation of LPA phosphatase
The GnRH agonist, buserelin, increased LPA phosphatase activity in plasma membranes of GnRH receptor-positive ovarian cells in the presence of the nonhydrolyzable GTP analog GTP-␥-S (Fig. 4) . The effect of buserelin on monoglyceride production was dose dependent, with a halfmaximal effect occurring with 30 nmol/L buserelin. GnRH agonist in the absence of GTP-␥-S had no effect on LPA phosphatase activity. GDP-␤-S completely reversed the stimulated phosphatase activity (Fig. 4) . Similar results were obtained with another GnRH agonist, leuprolide (data not shown). Control peptide, TRH (1 mol/L), had no effect in the presence of GTP-␥-S (Fig. 4, upper panel) . LPA phosphatase activity in plasma membranes of GnRH receptornegative tumors (cases 10 and 12, Table 1 ) was not altered by GnRH agonist (Fig. 4, lower panel) , providing further evidence of specificity.
Ovarian cancers contain heterogeneous cell types, including cancer cells, stromal cells, lymphocytes, endothelial cells, and platelets. To assess whether GnRH analogs increase LPA phosphatase activity in ovarian cancer cells and whether the effects of activation of the GnRH receptor observed in cell membranes might occur in intact cells, LPA phosphatase activity was examined in membranes from Caov-3 ovarian cancer cells pretreated with or without the GnRH agonist buserelin (Table 2) . LPA phosphatase activity was approximately 2.1-fold higher in membranes isolated from Caov-3 cells incubated with buserelin before lysis than in membranes from control cells.
LPA phosphatase activation associated with GnRH receptor occupancy
To determine whether GnRH receptor occupancy was specifically linked to increased LPA hydrolysis, we used antide, a drug that displaces bound GnRH from its receptors and serves as a competitive antagonist of GnRH action. As shown in Fig. 5 , after 30 min of incubation with buserelin, the addition of 10 mol/L antide, a dose that displaces virtually all of the GnRH agonist under these conditions (26, 27) , abolished buserelin-stimulated LPA dephosphorylation. These findings suggest that continued GnRH receptor occupancy was necessary for ongoing LPA hydrolysis.
Discussion
LPA degradation may be crucial to the termination of its activity on both normal and malignant cells. LPA can be degraded by PAPs and by (lyso)phospholipases (11) . In clinical specimens of surgically removed ovarian cancer, we first found that a LPA phosphatase in the plasma membrane was the predominant mediator of LPA degradation, and LPA lysophospholipase activity was very low. Further the GnRH receptor couples to the LPA phosphatase activity in membranes from GnRH receptor-positive cells.
LPA phosphatase activity in ovarian cell membrane most closely resembles PAP (23, 28) . To date, two LPA/PA phosphatase families have been identified. PAP type 1 (PAP1) is predominantly present in cytosol and microsomes (29, 30) , whereas PAP type 2 (PAP2) is localized in the plasma membrane (24, 31, 32) . Three PAP2 isozymes have been cloned and demonstrated to hydrolyze LPA (32, 33) . PAP1 requires Mg 2ϩ and is completely inhibited by NEM (23) (24) (25) . In contrast, PAP2 does not require Mg 2ϩ , and its activity is not inhibited by NEM (23) (24) (25) . As ovarian cancer plasma membrane LPA phosphatase activity was Mg 2ϩ independent and NEM insensitive, PAP2 is likely to be the predominant enzyme(s) responsible for LPA hydrolysis in ovarian cancer membrane. PAP2 is proposed to place the catalytic site in the extracellular space (34, 35) . The likely transmembrane topology of the PAP2 may be consistent with its physiological role to attenuate cell proliferation through the conversion of exogenous LPA to its dephosphorylated counterpart.
The GnRH receptor is a member of the family of GTPbinding protein-coupled receptors that possess seven transmembrane domains (36) . There are striking differences in the signal transduction pathways activated by GnRH receptors in ovarian cancer cells and anterior pituitary cells; the GnRH receptor in ovarian cancer couples to the G i family (17, 26) , whereas the GnRH receptor in pituitary gonadotrophs cells couples to the subfamily (37, 38) of G proteins. In the cell-free system, hormones that bind to a specific GTP-binding protein coupled receptor require the copresence of a nonhydrolyzable GTP analog to reveal their hormonal effects (39) . In the plasma membrane of GnRH receptor-bearing ovarian cancer, we found that 1) GnRH agonists increase LPA phosphatase activity; 2) GTP-␥-S was essential for the GnRH agonist to stimulate LPA phosphatase activity, and nonhydrolyzable GDP-␤-S reversed the GnRH action; and 3) membranes from GnRH receptor-negative specimens did not demonstrate increased LPA phosphatase activity in response to GnRH stimulation. GnRH-stimulated LPA dephosphorylation was neutralized by the competitive antagonist, antide. Detergents such as Triton X-100 (0.1%) caused severalfold increases in the basal activity of LPA dephosphorylation (data not shown), as previously described (23) (24) (25) . However, GnRH had no activating effect in the presence of the detergent. This may be caused by nonspecific perturbation of the structure of the plasma membranes by detergents.
Ovarian cancers contain multiple cell types, including cancer cells, stromal cells, and blood vessels. Our specimens may also contain platelets, which can produce and release LPA (40) . Ovarian cancer cells can produce LPA, at least in vitro (41) . Further, the elevated LPA levels in ovarian cancer patient plasma suggest that ovarian cancer cells may contribute to LPA production in vivo. We demonstrated that treatment of intact Caov-3 cells with GnRH agonists increased LPA phosphatase activity in cell membranes. Thus, ovarian cancer cells might display GnRH-responsive LPA phosphatase activity in vivo. As GnRH agonists decrease the growth of GnRH receptor-positive ovarian cancer cells, and LPA can increase the growth of ovarian cancer cells, increased LPA hydrolysis may contribute to the effects of GnRH on ovarian cancer cells. These findings also allowed us to draw two important conclusions: 1) activation of the GnRH receptor can increase LPA phosphatase activity; and 2) continued receptor occupancy was necessary for ongoing LPA hydrolysis.
Lastly, we demonstrated that hormonal activation of phosphatase may contribute to the majority of LPA loss at the level of plasma membrane in GnRH receptor-expressing ovarian carcinoma. Membranes from ovarian cancers have low levels of LPA lysophospholipase activity; however, this was less than 1% of the LPA phosphatase activity. The LPA phosphatase activation linked to GnRH receptor occupancy may at least partially mediate the antiproliferative action of GnRH agonist by release of LPA stimulation to promote cell growth. Although our data were derived from experiments that used surgically removed ovarian cancers as well as an ovarian cancer cell line in vitro, GnRH-induced LPA hydrolysis may play a role in LPA homeostasis and effects of GnRH in vivo.
